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OBJECTIVES This study presents clinical data from the first large registry of aortic counterpulsation, a
computerized database that incorporates prospectively gathered data on indications for
intra-aortic balloon counterpulsation (IABP) use, patient demographics, concomitant med-
ication and in-hospital outcomes and complications.
BACKGROUND The intra-aortic balloon pump (IABP) is widely used to provide circulatory support for
patients experiencing hemodynamic instability due to myocardial infarction, cardiogenic
shock, or in very high risk patients undergoing angioplasty or coronary artery bypass grafting.
METHODS Between June 1996 and August 2000, 203 hospitals worldwide (90% U.S., 10% non-U.S.)
collected 16,909 patient case records (68.8% men, 31.2% women; mean age 65.9  11.7
years).
RESULTS The most frequent indications for use of IABP were as follows: to provide hemodynamic
support during or after cardiac catheterization (20.6%), cardiogenic shock (18.8%), weaning
from cardiopulmonary bypass (16.1%), preoperative use in high risk patients (13.0%) and
refractory unstable angina (12.3%). Major IABP complications (major limb ischemia, severe
bleeding, balloon leak, death directly due to IABP insertion or failure) occurred in 2.6% of
cases; in-hospital mortality was 21.2% (11.6% with the balloon in place). Female gender, high
age and peripheral vascular disease were independent predictors of a serious complication.
CONCLUSIONS This registry provides a useful tool for monitoring the evolving practice of IABP. In the
modern-day practice of IABP, complication rates are generally low, although in-hospital
mortality remains high. There is an increased risk of major complications in women, older
patients and patients with peripheral vascular disease. (J Am Coll Cardiol 2001;38:1456–62)
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The intra-aortic balloon pump (IABP) is the most widely
used of all circulatory assist devices today (1). The IABP
was first employed 30 years ago as a treatment of last resort
for a mortally ill patient suffering from cardiogenic shock
(2,3). Today, this treatment modality is routinely used in a
wide range of serious cardiovascular conditions, ranging
from hemodynamic stabilization in patients suffering from
complications of acute myocardial infarction (AMI) or
cardiogenic shock, to very high risk patients undergoing
angioplasty or coronary artery bypass grafting (CABG)
(4–6).
As potential clinical applications of counterpulsation
continue to expand, there is an increasing need to prospec-
tively document the current clinical experience with IABP.
No study has extensively documented the indications, clin-
ical outcomes, patient hemodynamics, concomitant medi-
cations, complications, risk factors and insertion techniques
associated with IABP. Therefore, a comprehensive, pro-
spective, multicenter computerized database program was
developed: the Benchmark Counterpulsation Outcomes
Registry. The present report summarizes the development
and implementation of the registry, and reviews cumulative
data compiled from 17,540 IABP records from 16,909
patients between the initiation of data collection in June
1996 and August 2000.
METHODS
The Benchmark Counterpulsation Outcomes Registry was
started in June 1996, initially included 22 contributing
clinical centers, and presently includes 243 institutions in 18
countries. An independent steering committee (Appendix
A) designed and implemented the investigator-initiated
registry. Datascope Corp. (Fairfield, New Jersey) provided
funding for the database, and the sites included in the
registry were institutions that used intra-aortic balloons
(IABs) manufactured by Datascope Corp. Patient popula-
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tions included all patients in participating institutions who
received IABP between June 1996 (or time of institution
enrollment) and August 2000. Concomitant medications
and procedures were left to the discretion of the treating
physician.
Figure 1 outlines data handling within the registry.
Participating sites were provided with a computer for
entering data on all consecutive IABP cases. Database
software (Lotus Notes platform) was custom-written so
investigators could easily enter clinical data relating to
indications of IABP, details of the balloon insertion, patient
hemodynamics, concomitant medications, complications
and in-hospital outcomes. Site data were forwarded via
modem to a single registry storage location and handled on
a central file server. Continuous updates, individual site data
and registry information were available on-line at the
participating sites. More complex data queries were per-
formed by request at the central storage facility.
Statistics. Descriptive summaries included frequency and
percent distributions for the categorical variables, and the
sample mean, standard deviation, minimum, median and
maximum for the quantitative assessments. Logistic regres-
sion methodology was used to study effects of demographic,
medical history and preprocedure factors on the occurrence
of a major IABP complication. A full model containing all
selected factors was first obtained, then a reduced model was
generated containing only those factors that individually
tested as statistically significant (p  0.05) within the
model. The reduced model also had to fit as well as the full
model as measured by the reduction in the likelihood ratio
chi-square statistic. All analyses were performed using SAS,
version 8, using the Windows 98 operating system from an
IBM-compatible PC.
End points. We collected data on four primary end points:
ischemia, bleeding, IABP failure and in-hospital mortality.
Major limb ischemia was defined as a loss of pulse or
sensation, or abnormal limb temperature or pallor, requiring
surgical intervention. Minor ischemia was defined as de-
creased arterial flow as manifested by diminished pulse that
resolves with balloon removal, and not resulting in any
impairment of body function.
An association with hemodynamic compromise, required
blood transfusion or surgical intervention defined severe
bleeding. Nonsevere bleeding involved minor hematomas
and oozing from puncture site, and did not require blood
transfusion or surgical intervention. The IAB failure was
defined as poor augmentation, inability to deploy or any
IAB leak suggested by blood inside the catheter tubing, gas
loss or catheter alarm. All-cause hospital mortality was
defined as mortality occurring from any cause during IABP
or after IABP. Mortality directly related to IABP was also
tabulated. A secondary endpoint was major IAB-related
complications, defined as any major limb ischemia, severe
bleed, IAB leak or mortality directly attributed to IABP.
Registry validation. In order to maximize the reliability of
the registry from which these data were gathered, an
external audit (data validation) of the Benchmark Registry
was undertaken (StatTrade, Inc., Morrisville, Pennsylvania)
that was sponsored by Datascope. Randomly selected data-
base case histories from 21 hospitals with 2,339 patient
records were audited and compared to actual local site
records. The audit involved 485 (20.7%) records entered in
1999. Seventy items were checked from each record, result-
ing in an audit of 33,950 entries. Check-box items had at
least a 95% accuracy (lower 95% confidence bound), and
dates had at least a 90% accuracy. In addition, virtually all
IABP cases were being reported by each participating
hospital.
RESULTS
Clinical variables and indications. Between June 1996
and September 2000, 16,909 individual IABP patients were
enrolled in the database. Of the enrolled patients, 68.8%
were male, 31.2% were female and the mean age was 65.9
years (Table 1). From the perspective of clinical history,
25.6% of patients had diabetes, 11.9% had peripheral
vascular disease (PVD), 30.6% had experienced a prior
myocardial infarction and 14.6% had undergone prior
CABG surgery. In 15.4% of patients, the presenting symp-
Abbreviations and Acronyms
AMI  acute myocardial infarction
BSA  body surface area
CABG  coronary artery bypass graft
IAB  intra-aortic balloon
IABP  intra-aortic balloon pump
LOS  length of stay
PVD  peripheral vascular disease
Figure 1. Data handling in the Benchmark Registry. Data from consecu-
tive patients are collected at participating centers, entered into a computer
on-site and subsequently transferred to a central storage facility. Individual
site and overall registry data are available to the participants, as well as
customized queries of the database.
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toms involved the left main coronary artery, while 28.5%
had triple-vessel disease. Some of the patients only under-
went diagnostic catheterization procedures (9.3%) or percu-
taneous coronary intervention procedures (23.0%); the ma-
jority of procedures were surgical (60.7%; 89.4% of the
surgical patients were undergoing CABG). Of the total
16,909 patients, 13,020 (77%) underwent cardiac catheter-
ization and 4,833 (28.6%) underwent percutaneous coronary
intervention. Of the 9,179 patients undergoing CABG
surgery, 1,672 (18.2%) underwent CABG alone, 6,655
(72.5%) underwent diagnostic catheterization and CABG,
and 852 (9.3%) underwent percutaneous coronary interven-
tion and CABG.
The most frequent indication for use of IABP was to
provide hemodynamic support during or after cardiac cath-
eterization (20.6% of patients) (Table 2). Other common
clinical indications included cardiogenic shock (18.8%),
weaning from cardiopulmonary bypass (16.1%), refractory
unstable angina (12.3%) and preoperative use in high risk
patients (13.0%).
Balloon insertion. Balloon insertions were performed in
the catheterization laboratory or procedure room (63.0%),
the operating room (24.0%), the intensive care unit (4.0%),
the emergency department (0.2%) and other locations
(8.8%). Patients received either 40 ml (77.3%), 34 ml
(21.5%) or other size balloons (1.2%). Insertion technique
involved a sheath in 79.7% of patients, and employed a 9.5F
(78.4%) or an 8F catheter (21.6%; 8F devices have been
available since June 1, 1997). The insertion was accom-
plished percutaneously in 95.4% of cases. The approach was
right femoral (63.3%), left femoral (35.6%) or an alternate
approach (1.1%). The mean duration of IABP in the overall
registry cohort was 53 h (median  41 h, most frequent
time  24 h, range from 5 min to 89 days).
In-hospital balloon-related complications. The inci-
dence of balloon-related complications in the overall registry
cohort was low (Table 3). Major complications of balloon
counterpulsation were defined as severe bleeding, major
limb ischemia, balloon leak or in-hospital mortality related
to IABP. A total of 2.6% of all patients experienced at least
one major complication.
Limb ischemia (defined as reduced arterial flow as man-
ifested by diminished pulse) occurred in 2.9% of cases, but
major limb ischemia (loss of pulse, loss of sensation,
abnormal limb temperature or pallor requiring surgical
intervention, arterial repair or amputation) was reported in
Table 1. Baseline Demographics
Total
Population
(n  16,909)
Diagnostic
Catheterization Only
(n  1,576)
Catheterization
and PCI Only
(n  3,882)
Surgery
No Intervention or
Revascularization
Noted (n  1,186)
CABG
(n  9,179)
Non-CABG
(n  1,086)
Age, yr, mean (SD) 65.9 (11.7) 66.2 (12.2) 65.5 (12.4) 66.5 (10.8) 63.4 (13.5) 64.1 (13.3)
Proportion of women (%) 31.2 31.7 31.9 31.0 37.4 23.4
BSA m2, mean (SD) 2.0 (0.2) 2.0 (0.3) 2.0 (0.2) 2 (0.2) 1.9 (0.2) 1.9 (0.2)
History of diabetes (%) 25.6 26.1 24.1 27.9 22.2 14.4
PVD (%) 11.9 11.9 9.8 13.5 11.0 7.9
Previous MI (%) 30.6 30.1 28.0 33.8 25.5 19.6
Previous CABG (%) 14.6 14.6 16.9 13.4 20.9 11.2
BSA  body surface area; CABG  coronary artery bypass graft; MI  myocardial infarction; PCI  percutaneous coronary intervention; PVD  peripheral vascular disease.
Table 2. Indications for Use
Total
Population
(n  16,909)
Diagnostic
Catheterization Only
(n  1,576)
Catheterization
and PCI Only
(n  3,882)
Surgery
No Intervention or
Revascularization
Noted (n  1,186)
CABG
(n  9,179)
Non-CABG
(n  1,086)
Support and stabilization (%) 20.6 21.4 54.4 9.7 5.0 7.8
Cardiogenic shock (%) 18.8 33.1 23.7 12.3 23.8 29.4
Weaning from cardiopulmonary
bypass (%)
16.1 0.4 0.1 24.9 31.4 7.1
Preop: high risk CABG (%) 13.0 4.6 0.2 22.1 6.4 1.9
Refractory unstable angina (%) 12.3 15.3 8.3 15.8 2.2 3.0
Refractory ventricular failure (%) 6.5 9.1 2.5 5.9 15.7 12.7
Mechanical complication due to
AMI (%)
5.5 9.8 7.0 4.2 5.2 5.1
Ischemia related to intractable
VA (%)
1.7 1.6 1.5 1.9 1.7 1.6
Cardiac support for high risk
general surgery patients (%)
0.9 2.1 0.2 0.5 4.3 1.1
Other (%) 0.8 0.7 0.2 0.8 2.5 2.0
Intraoperative pulsatile flow (%) 0.4 0.1 0.1 0.7 0.5 0.2
Missing indication (%) 3.3 1.8 1.9 1.2 1.5 28.1
AMI  acute myocardial infarction; CABG  coronary artery bypass graft; PCI  percutaneous coronary intervention; VA  ventricular arrhythmias.
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only 0.9% of patients. Balloon leak occurred in 1.0% of
cases. The incidence of severe bleeding (bleeding at the
balloon insertion site leading to hemodynamic compromise
and requiring a transfusion or surgical intervention) was
0.8%. Of the balloon insertions, 2.6% were unsuccessful due
to a balloon leak, poor inflation of a balloon, poor augmen-
tation or difficulties associated with balloon insertion (Table
4). The incidence of in-hospital mortality related to IABP
was 0.05%. Not surprisingly, overall in-hospital mortality in
this seriously ill population was high (21.2%, 11.6% with the
IAB in place). The mean length of stay (LOS) in this cohort
was 14 days (median  10 days, most frequent LOS  7
days, range from 1 day to 384 days).
Multivariate logistic regression analysis was used to iden-
tify significant independent predictors of a major complica-
tion of IABP, including death related to IABP, major limb
ischemia, severe bleeding or balloon leak. Of the 15 vari-
ables screened, only female gender, PVD, small body surface
area (BSA) (1.65 m2) and higher age (75 years) signif-
icantly increased the risk of a major complication. Table 5
identifies the risk factors in order by odds ratio.
DISCUSSION
The major finding of this study is that the incidence of
major balloon-related complications is encouragingly low
(2.8%). Advances such as percutaneous insertion and
smaller-diameter catheters have considerably reduced the
incidence of serious vascular complications (7–23). In addi-
tion, the incidence of unsuccessful IABP due to balloon
leak, poor inflation, poor augmentation or insertion diffi-
culty was extremely low (2.3%), and to our knowledge, no
previous study has examined this issue.
Complications and risk factors. The overall complication
rates noted in this real-world observational experience
compare favorably with other published observational expe-
riences (Table 6) (24–26). Both major limb ischemia (0.9%)
and major bleeding (0.8%) are lower than in the previously
reported experiences; this may be due to use of smaller
catheters and advances in the use of heparin and glycopro-
tein inhibitors. Use of the IABP has been shown to reduce
recurrent ischemia (24) and improve overall clinical out-
comes (4). In the present study, the actual number of deaths
attributable to IABP failure or insertion is approximately 5
in 10,000, with a low incidence of other balloon-related
complications, suggesting that IABP is a low risk therapeu-
tic option in a high risk patient cohort. In fact, previous
studies report low balloon-related mortality, and there
seems to be less balloon-related mortality over time (Table
6) (27).
Sheathless insertion techniques have not replaced the
Table 3. Summary of Outcomes/Complications
Total
Population
(n  16,909)
Diagnostic
Catheterization Only
(n  1,576)
Catheterization
and PCI Only
(n  3,882)
Surgery
No Intervention or
Revascularization
Noted (n  1,186)
CABG
(n  9,179)
Non-CABG
(n  1,086)
In-hospital mortality (%) 21.2 32.2 18.4 16.8 37.8 34.1
Mortality—balloon in place (%) 11.6 17.6 10.1 9.2 19.8 20.2
IABP-related mortality* (%) 0.05 0.1 0.1 0.0 0.0 0.1
Amputation† 0.1 0.0 0.1 0.1 0.1 0.0
Major limb ischemia‡ (%) 0.9 0.6 0.5 1.2 1.0 0.5
Any limb ischemia (%) 2.9 3.2 1.9 3.5 2.5 1.7
Severe access site bleeding (%) 0.8 0.8 1.2 0.7 0.7 0.3
Any access site bleeding (%) 2.4 2.7 4.4 1.7 1.3 1.4
Balloon leak (%) 1.0 0.9 0.8 1.1 0.5 1.6
Composite outcomes
Major IABP complication§ (%) 2.8 2.8 2.2 3.0 2.9 2.4
Any IABP complication (%) 7.0 7.6 7.5 7.1 6.0 5.2
Any unsuccessful IABP¶ (%) 2.3 2.5 1.7 2.5 2.4 2.7
*Death as direct consequence of IABP therapy. †All major limb ischemia. ‡Loss of pulse or sensation, abnormal limb temperature or pallor, requiring surgical intervention.
§Balloon leak, severe bleeding, major limb ischemia or death as a direct consequence of IABP therapy. Any access site bleeding, any limb ischemia, balloon leak, poor inflation,
poor augmentation, insertion difficulty or death as direct result of IABP therapy. ¶Balloon leak, poor inflation, poor augmentation or insertion difficulty.
CABG  coronary artery bypass graft; IABP  intra-aortic balloon pump; PCI  percutaneous coronary intervention.
Table 4. Unsuccessful IABP*
Total
Population
(n  389)
Diagnostic
Catheterization Only
(n  39)
Catheterization
and PCI Only
(n  66)
Surgery
No Intervention or
Revascularization
Noted (n  32)
CABG
(n  229)
Non-CABG
(n  26)
Balloon leak (%) 52.2 60.6 35.3 52.1 50.1 66.7
Poor inflation (%) 21.7 16.2 35.5 20.0 20.8 18.5
Difficult insertion (%) 13.0 4.0 5.9 16.0 4.2 14.8
Poor augmentation (%) 39.1 40.4 35.3 40.1 41.8 25.9
*Individual patients may have more than one reason for an unsuccessful IABP.
CABG  coronary artery bypass graft; PCI  percutaneous coronary intervention.
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traditional insertion techniques, although this may change
in the future. The Benchmark experience to date has only
recently (since June 1997) included 8F devices, but usage
rates of these smaller catheters are expected to increase as
more centers seek to reduce access site injury.
Previous studies have implicated patient size, diabetes
and PVD as major IABP risk factors, but have generally
been small and retrospective in nature. Multivariate logistic
regression (not stepwise) on the present data establish that
female gender, PVD, BSA (1.65 m2) and age (75 years)
remain the four prominent, independent predictors of a
serious IABP complication. These four high risk groups
may become a focus of efforts to improve clinical outcomes
and to reduce IABP complications.
Indications. The American College of Cardiology/American
Heart Association guideline indications for IABP use in-
clude preparation for angiography and revascularization in
cardiogenic shock that has not quickly reversed, acute mitral
regurgitation or ventricular septal defect, refractory post-MI
angina, refractory ventricular arrhythmias with hemody-
namic instability, hemodynamic instability, poor left ven-
tricular function or recurrent ischemia (28). However, no
study other than this one has examined indications for
IABP use. The data from this registry suggest that the most
frequent indication for IABP was to provide hemodynamic
support in the catheterization laboratory, and the most
frequent site of IAB insertion was in the catheterization
laboratory. Thus, IABP appears to have been embraced as
an adjunctive technique in patients undergoing invasive
cardiac procedures. The mean duration of hemodynamic
support was 53 h, verifying the use of IABP for short-term
hemodynamic support. The IABP was also widely used in
patients with cardiogenic shock and in patients undergoing
high risk surgical procedures. Interestingly, although
CABG is considered a primary indication for IABP use,
only 13% of patients received an IABP because they were
undergoing a CABG procedure (Table 2). However, of the
patients who received an IABP, more than half underwent
CABG even if it was not the primary indication.
Registry information. The National Registry of Myocar-
dial Infarction is an ongoing, prospective registry that
provides a framework for this registry (29). The ongoing
Benchmark Counterpulsation Outcomes Registry provides
prospective data on all patients who receive IAB counter-
pulsation (IABP) support at over 243 hospitals in 18
countries. The database has considerable potential for ex-
amining current practice patterns, documenting outcome,
and trending use and outcomes over time. For example, the
impact of such advances as the recently released 8F balloon
catheter system can be rigorously and prospectively evalu-
ated through use of the IABC registry data. In addition,
data from this registry will be used as a complement to
standards based assessment (Appendix B).
Table 5. Risk Factors for Major Complications of IABP*
Risk Factor
Estimated Odds Ratio
(Presence/Absence)
95%
Confidence
Limits p Value
PVD 1.968 1.557, 2.487 0.001
Female 1.737 1.414, 2.134 0.001
BSA 1.65 m2 1.453 1.095, 1.926 0.05
Age 75 yrs 1.289 1.048, 1.585 0.05
*The chi-square was highly significant (p  0.001); however, the concordance index
was only 61%. The following variables were tested, but were not significant: primary
intervention, history of diabetes, previous myocardial infarction, previous coronary
artery bypass graft, indications for use (cardiogenic shock, wean from cardiopulmo-
nary bypass), primary/tertiary care institution, catheter size and left vessel main
involvement.
BSA  body surface area; IABP  intra-aortic balloon pump; PVD  peripheral
vascular disease.
Table 6. IABP Complications and In-Hospital Mortality
Study n Dates
Major
Bleed
Major
Limb
Ischemia
Balloon-
Associated
Mortality
Hospital
Mortality
Present study 16,909 1996–2000 0.8% 0.9% 0.05% 21.2%
Makhoul et al. (7) 436 1971–1985 1.1% 8.3% 0.5% NR
Iverson et al. (13) 395 1973–1986 NR 10.9% NR 47%
Gottlieb et al. (11) 206 1980–1982 NR 10% 0.5% 33%
Arafa et al. (25) 509 1980–1994 2.0% 7.5% 0.6% 49.1%
Alderman et al. (12) 106 1983–1986 NR 14.2% 0.9% 17.9%
Barnett et al. (8) 580 1983–1990 NR 11.9% 0.5% 44%
Eltchaninoff et al. (17) 231 1985–1990 3.5% 3.9% 0 NR
Busch et al. (26) 472 1985–1995 3.2% 27.5% 0.0% 28.3%
Funk et al. (15) 294* 1986–1987 NR 11.7% NR NR
Kvilekval et al. (22) 144 1986–1989 NR 10.4% NR 17%
Miller et al. (16) 404† 1987–1989 NR 10% NR 30%
Pi et al. (27) 129 1988–1992 14.7%‡ 4.6% NR 49.6%
Tartar et al. (20) 126 1988–1992 3.2% 12.2%‡ 0 23.8%
Gol et al. (21) 493 1988–1993 5.1% 14% 2.6% 53.2%
Patel et al. (9) 691 1993–1995 3.5% 4% 0.4% NR
Winters et al. (23) 870 1993–1996 6.9% 3.3% 0.2% NR
Cohen et al. (10) 1119 1993–1997 4.6% 3.3% 0.4% NR
*9 died acutely. †48 died acutely. ‡Combined major and minor. §30-day mortality.
IABP  intra-aortic balloon pump; NR  not reported.
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Study limitations. The limitations of the present study are
those inherent in any large-scale retrospective observational
registry. This is not a randomized trial; rather, it is a detailed
description of ongoing and evolutionary clinical practice.
Most of the data were collected prospectively, however,
some were collected based on review of patient charts and
records. The data have not been 100% validated, but in
contrast to other large-scale observational registries, the
Benchmark registry has gone to considerable effort to
validate the data. Finally, given the large number of partic-
ipating clinical institutions, there are site-to-site variations
in personnel and resources allocated to the registry, individ-
ual practice patterns and patient populations.
Retrospective analyses of risk factors should be regarded
with caution because there is not necessarily a cause and
effect relationship with the risk factors associated with major
complications. However, the data strongly suggest the need
for greater care and clinical attention in treating patients
who are small, female, have PVD or who are at least 75
years of age, in view of their increased risk for experiencing
a major complication of IABP.
Summary. In this analysis if 16,909 patients enrolled form
June 1996 to August 2000, the incidence of major compli-
cations was relatively low (2.8%) as were incidences of
unsuccessful IABP (2.3%). In addition, the most frequent
indication for use of IABP was for hemodynamic support in
the catheterization laboratory, while use of IABP during
CABG procedures remained relatively low. Female gender,
small BSA, high age and PVD were independent predictors
of a serious complication of IABP.
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APPENDIX B
The Joint Commission on Accreditation of Healthcare
Organizations (JCAHO) has recently introduced the
ORYXtm initiative to integrate performance measures into
the accreditation process and establish a data-driven con-
tinuous survey to complement standards-based assessment.
The JCAHO has accepted the Benchmark Counterpulsa-
tion Outcomes Registry as having met the initial criteria for
inclusion in the ORYXtm initiative, which measures clinical
performance as a part of the future accreditation process. A
total of 8 Benchmark measures of clinical outcome have
been accepted by the Joint Commission for accreditation
purposes in connection with the ORYXtm initiative.
APPENDIX C: PARTICIPATING SITES
Australia (1 Participant)
Alfred Hospital; Prahran, Victoria, Australia
Belgium (5 Participants)
Centre Hospitalier Sart Tilman; Liege, Belgium
Clinique Universitaire; Yvoir, Belgium
Hopital de la Citadelle; Liege, Belgium
Universitair Ziekenhuis Antwerpen; Eilegem, Belgium
Universitair Ziekenhuis; Gent, Belgium
Brazil (1 Participant)
Hospital Sao Mateus S/C Ltda.; Papicua, Forteleza, Brazil
Canada (11 Participants)
Centre Hospitalier de la Vallee de l’Outaouais; Hull, Que-
bec, Canada
CHUM-Campus Notre Dame; Montreal, Quebec, Canada
Foothills Provincial General; Calgary, Canada
Hopital St-Luc; Montreal, Quebec, Canada
Institut De Cardiologie De Montreal; Montreal, Canada
Kingston General Hospital; Kingston, Ontario, Canada
London Health Service University Campus-Windemer;
London ON, Canada
London Health Services Victoria Campus-South St.; Lon-
don ON, Canada
Royal University Hospital; Saskatoon, Saskatchewan, Can-
ada
Sudbury Regional Hospital; Sudbury, Ontario, Canada
Vancouver Hospital & Health Sciences Center; Vancouver,
British Columbia, Canada
Denmark (1 Participant)
Skeijby Universitetshospital; Aarhus, Denmark
France (10 Participants)
Centre Medico-Chirurgical PARLY II; France
CHR Rennes; France
CHU Bon Secours, METZ; METZ Cedex, France
CHU Michallon Grenoble; Grenoble, Cedex, France
CHU Toulouse Hopital Rangueil; Toulouse, France
Hopital de la Timone; Marseille, France
Hopital Louis Pradel; Bron, France
Hopital Pastuer; Nice, France
Hopital Saint Joseph; Marseille, France
Institut Jacques Cartier; Massy, France
Germany (15 Participants)
Berufsgenossenschaftliche Kliniken Bergmannsheil Univer-
sitatsklinik; Bochum, Germany
Friedrich-Schiller-Universita¨t Jena-Klinik fu¨r Innere Medi-
zin 3-; Jena, Germany
Herzzentrum Frankfurt AG; Franfurt, Germany
Herzzentrum Lahr/Baden; Lahr, Germany
Kaiser Wilhelm-Krankenhaus; Duisburg, Germany
Klinikum der Phillipps-Universita¨t Marburg/Lahn; Mar-
burg, Germany
Klinikum Karlsburg Klinik fu¨r Ana¨sthesiologie und Inten-
sivmedizin; Karlsburg, Mecklenburg-Vorpommern,
Germany
Klinikum Krefeld; Krefeld, Germany
Kreiskrankenhaus Vo¨klingen; Vo¨klingen, Germany
Medizinische Einrichtungen der RWTH; Aachen, Ger-
many
Sta¨dtische Kliniken Dortmund Klinik fu¨r Thorax-, Herz-
und Gefa¨sschirurgie Prof. Dr. med. M.-J. Polonius;
DORTMUND, Germany
Uniklinik Bonn; Bonn, Germany
Universita¨tsklinik Go¨ttingen; Go¨ttingen, Germany
University-Hospital Luebeck; Luebeck, Germany
University of Gießen; Gießen, Germany
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Ireland (1 Participant)
Mater Misecordiae Hospital; Dublin, Ireland
Italy (4 Participants)
Centro Cuore Columbus; Milan, Italy
Ospedale Clinicizzato San Donato; San Donato Milanese,
Italy
Ospedale di Mirano; Mirano (Venezia), Italy
Poliambulanza; Brescia, Italy
Netherlands (6 Participants)
Academisch Ziekenhuis Masstricht; Maastricht, Nether-
lands
Academisch Ziekenhuis Vrije Universiteit; HV Amster-
dam, Netherlands
Leids Universtaire Medische Centrum (LUMC); Za Lei-
den, Netherlands
Medische Centrum Alkmaar; JD ALKMAAR, Netherlands
Medische Spectrum Twente; JX ENSCHEDE, Netherlands
Weezenlanden Hospital; JW Zwolle., Netherlands
New Zealand (1 Participant)
Green Lane Hospital; Epsom Auckland, New Zealand
Poland (1 Participant)
Gornoslaskie Centrum; Poland
Scotland (1 Participant)
Aberdeen Royal Infirmary; Aberdeen, Scotland
South Africa (2 Participants)
Morningside Hospital; Johannesburg, South Africa
Union Hospital; Johannesburg, South Africa
Sweden (1 Participant)
University Hospital; Lund, Sweden
Switzerland (2 Participants)
Inselspital; Bern, Switzerland
La Tour Hospital; Meyrin, Geneva, Switzerland
United Kingdom (14 Participants)
Bristol Royal Infirmary; Bristol, United Kingdom
Cardiothoracic Center Liverpool; Liverpool, United King-
dom
Freeman Hospital; Newcastle Upon Tyne, United Kingdom
Glenfield Hospital; Leicester, United Kingdom
Harefield; Harefield, United Kingdom
Hull Royal Infirmary; Hull, United Kingdom
Morriston; Swansea, United Kingdom
Nottingham City; Nottingham, United Kingdom
Royal Sussex County; Brighton East Sussex, United King-
dom
South Cleveland Hospital; Middlesborough, Cleveland,
United Kingdom
The London Chest Hospital; London, United Kingdom
The Royal Brompton Hospital; London, United Kingdom
Walsgrave; Walsgrave, United Kingdom
Wythenshaw Hospital; Wythenshaw, Manchester, United
Kingdom
United States (166 Participants)
Alabama (6 Participants)
Baptist Medical Center; Montgomery, AL
Carraway Methodist Med. Center; Birmingham, AL
Jackson Hospital and Clinic; Montgomery, AL
Shelby Medical Center; Alabaster, AL
South Baldwin Hospital; Foley, AL
University of Alabama Hospital; Birmingham, AL
Arkansas (4 Participants)
Baptist Memorial Medical Ctr.; North Little Rock, AR
Northwest Medical Center; Springdale, AR
St. Vincent Infirmary-Med. Ctr.; Little Rock, AR
Univ. Hospital & Amb. Care Ctr.; Little Rock, AR
California (10 Participants)
Downey Community Hospital; Downey, CA
Good Samaritan Hospital; Los Angeles, CA
Grossmont Hospital; La Mesa, CA
Holy Cross Medical Center; Mission Hills, CA
Kaweah Delta District Hospital; Visalia, CA
Long Beach Memorial Med. Ctr.; Long Beach, CA
Providence of St. Joseph’s Medical Center; Burbank, CA
Santa Barbara Cottage Hospital; Santa Barbara, CA
Sharp Memorial Hospital; San Diego, CA
St. John’s Regional Medical Ctr.; Oxnard, CA
Colorado (2 Participants)
St. Anthony Hospital Central; Denver, CO
St. Mary’s Hospital and Med. Ctr.; Grand Junction, CO
Connecticut (2 Participants)
Bridgeport Hospital; Bridgeport, CT
St. Vincent’s Medical Center; Bridgeport, CT
Florida (15 Participants)
Broward General Medical Center; Ft. Lauderdale, FL
Charlotte Regional Med. Ctr.; Punta Gorda, FL
Columbia West Florida; Pensacola, FL
Florida Hospital-Orlando; Orlando, FL
Florida Medical Center; Ft. Lauderdale, FL
Largo Medical Center Hospital; Largo, FL
Lucerne Medical Center; Orlando, FL
Munroe Regional Medical Center; Ocala, FL
Naples Community Hospital; Naples, FL
North Ridge Medical Center; Ft. Lauderdale, FL
Sarasota Memorial Hospital; Sarasota, FL
Shands Hosp. at the Univ. of FL; Gainesville, FL
St. Joseph’s Hospital; Tampa, FL
Tallahassee Memorial Hospital; Tallahassee, FL
Veterans Affairs Medical Center; Gainesville, FL
Georgia (2 Participants)
Atlanta Medical Center; Atlanta, GA
Medical Center of Central Georgia; Macon, GA
Hawaii (1 Participant)
Kaiser Foundation Hospital; Honolulu, HI
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Idaho (1 Participant)
St. Alphonsus Regional Med. Ctr.; Boise, ID
Illinois (14 Participants)
Bromenn Regional Medical Ctr.; Normal, IL
E H S Christ Hospital & Med. Ctr.; Oak Lawn, IL
Gottlieb Memorial Hospital; Melrose Park, IL
Illini Hospital; Silvis, IL
La Grange Memorial Hospital; La Grange, IL
Mercy Ctr. for Health Care Services; Aurora, IL
Methodist Med. Ctr. of Illinois; Peoria, IL
Mt. Sinai Hosp. Med. Center; Chicago, IL
Northwest Community Hospital; Arlington Heights, IL
Proctor Hospital; Peoria, IL
St. Francis Medical Center; Peoria, IL
St. Joseph Medical Center; Joliet, IL
Trinity Medical Center; Rock Island, IL
Westlake Community Hospital; Melrose Park, IL
Indiana (3 Participants)
Bloomington Hospital; Bloomington, IN
Greater Lafayette Health Service, Inc.; Lafayette, IN
Witham Memorial Hospital; Lebanon, IN
Iowa (5 Participants)
Allen Memorial Hospital; Waterloo, IA
Mercy Medical Center; Cedar Rapids, IA
Mercy Medical Center; Dubuque, IA
St. Luke’s Methodist Hospital; Cedar Rapids, IA
Univ. of Iowa Hospitals; Iowa City, IA
Kansas (1 Participant)
Hutchinson Community Hospital; Hutchinson, MN
Louisiana (3 Participants)
Ochsner Foundation Hospital; New Orleans, LA
St. Frances Cabrini Hospital; Alexandria, LA
Terrebonne General Medical Ctr.; Houma, LA
Maine (1 Participant)
Maine Medical Center; Portland, ME
Maryland (1 Participant)
Washington Adventist Hospital; Takoma Park, MD
Massachusetts (2 Participants)
New England Medical Center; Boston, MA
St. Elizabeth’s Medical Center; Brighton, MA
Michigan (13 Participants)
Bronson Methodist Hospital; Kalamazoo, MI
Genesys Health Park; Grand Blanc, MI
Henry Ford Hospital; Detroit, MI
Ingham Regional; Lansing, MI
Mercy Hospital; Muskegon, MI
Mount Clemens General Hospital; Mt. Clemens, MI
Munson Medical Center; Traverse City, MI
Northern Michigan Hospital; Petoskey, MI
Sparrow Hospital; Lansing, MI
Spectrum Health Downtown; Grand Rapids, MI
St. Joseph Mercy Hospital; Ann Arbor, MI
St. Joseph Mercy Hospital; Pontiac, MI
William Beaumont Hosp. Royal Oak; Royal Oak, MI
Minnesota (4 Participants)
Fairview Southdale Hospital; Minneapolis, MN
Fairview University Hospital; Minneapolis, MN
Hennepin County Med. Center; Minneapolis, MN
North Memorial Medical Center; Robbinsdale, MN
Mississippi (1 Participant)
St. Dominic-Jackson Mem. Hosp.; Jackson, MS
Nebraska (1 Participant)
Nebraska Health Systems-University; Omaha, NE
New Hampshire (2 Participants)
Catholic Medical Center; Manchester, NH
Exeter Hospital; Exeter, NH
New Jersey (7 Participants)
Cooper Hospital/Univ. Med. Ctr.; Camden, NJ
Hackensack Medical Center; Hackensack, NJ
Jersey Shore Medical Center; Neptune, NJ
Newark Beth Israel Med. Center; Newark, NJ
Our Lady of Lourdes Med. Ctr.; Camden, NJ
Passaic General; Passaic, NJ
St. Joseph’s Hosp. and Med. Center; Paterson, NJ
New Mexico (1 Participant)
San Juan Regional Medical Ctr.; Farmington, NM
New York (11 Participants)
Albany Medical Center Hospital; Albany, NY
Arnot-Ogden Medical Center; Elmira, NY
Beth Israel Medical Center; New York, NY
Buffalo General Hospital; Buffalo, NY
Long Island Jewish Med. Ctr.; New York, NY
Millard Fillmore Hospital; Buffalo, NY
St. Elizabeth Hospital; Utica, NY
St. Joseph’s Hospital Health Ctr.; Syracuse, NY
St. Peter’s Hospital; Albany, NY
University Hospital Brooklyn; Brooklyn, NY
Winthrop-University Hospital; Mineola, NY
North Carolina (3 Participants)
Frye Regional Medical Center; Hickory, NC
Moore Regional Hospital; Pinehurst, NC
Wake County Medical Center; Raleigh, NC
Ohio (8 Participants)
Lima Memorial Hospital; Lima, OH
Miami Valley Hospital; Dayton, OH
Northside Medical Center; Youngstown, OH
Ohio State Univ. Hospital; Columbus, OH
St. Rita’s Medical Center; Lima, OH
St. Vincent Mercy Medical Center-Cardiac Cath. Lab;
Toledo, OH
St. Vincent Mercy Medical Center-Perfusion; Toledo, OH
University Hospital; Cleveland, OH
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Oklahoma (4 Participants)
Integris Baptist Med. Ctr.; Oklahoma City, OK
Midwest City Regional Hospital; Midwest City, OK
St. Anthony Hospital; Oklahoma City, OK
St. Francis Hospital; Tulsa, OK
Pennsylvania (9 Participants)
Altoona Hospital; Altoona, PA
Doylestown Hospital; Doylestown, PA
Hahnemann Univ. Hospital; Philadelphia, PA
Hamot Medical Center; Erie, PA
Lancaster General Hospital; Lancaster, PA
Medical College of PA Hospital; Philadelphia, PA
Robert Packer Hospital; Sayre, PA
St. Francis Medical Center; Pittsburgh, PA
UPMC Lee Regional; Johnstown, PA
Rhode Island (1 Participant)
Miriam Hospital; Providence, RI
South Carolina (3 Participants)
Carolinas Hosp. Syst./Florence; Florence, SC
Grand Strand General Hospital; Myrtle Beach, SC
Hilton Head Hospital; Hilton Head, SC
Tennessee (3 Participants)
Erlanger Medical Center; Chattanooga, TN
Univ. of Tenn. Mem. Hospital; Knoxville, TN
Vanderbilt University Medical Center; Nashville, TN
Texas (12 Participants)
Baptist Hospital Southeast Texas; Beaumont, TX
Bayshore Medical Center (PerStat Medical Systems); Clear
Lake, TX
Columbia Medical Center West; El Paso, TX
Harris Methodist/H E B North; Bedford, TX
Heart Hospital of Austin; Austin, TX
Houston Northwest Medical Ctr.; Houston, TX
Mc Allen Heart Hospital; Mc Allen, TX
Medical City Dallas Hospital; Dallas, TX
Osteopathic Med. Ctr. of Texas; Ft. Worth, TX
Santa Rosa Northwest Hospital; San Antonio, TX
Seton Medical Center; Austin, TX
St. Luke’s Episcopal Hospital; Houston, TX
Virginia (3 Participants)
Henrico Doctors Hospital; Richmond, VA
Sentara Norfolk General Hosp.; Norfolk, VA
Southside Regional Medical Ctr.; Petersburg, VA
Washington (1 Participant)
Providence Yakima Medical Center; Yakima, WA
West Virginia (2 Participants)
Charleston Area Med. Ctr.-Gen. Div.; Charleston, WV
St. Mary’s Hospital; Huntington, WV
Wisconsin (3 Participants)
Appleton Medical Center; Appleton, WI
Mercy Hospital of Janesville; Janesville, WI
St. Mary’s Medical Center; Racine, WI
Wyoming (1 Participant)
Wyoming Medical Center; Casper, WY
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